MDRNA’s siRNA Delivery Technology Shows Positive Results
In the study, neither change in particle characteristics such as size or charge nor loss in siRNA integrity was observed. The company’s proprietary UsiRNA constructs in the DiLA2
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).